F127 - Fifty Shades of Brown - Science, Symptoms, and Strategies for Acquired Pigmentary Disorders
Monday, February 19; 9:00 AM - 11:00 AM
Following this course, the attendee should be able to:
- Define the proper methods for diagnosing and documenting dyschromia in patients with various ethnic backgrounds
- Discuss the most recent scientific breakthroughs in our understanding of normal melanocyte biology and abnormal pigment physiology
- Formulate medical, surgical, or combination treatment strategies for common pigmentary conditions
Acquired pigmentary disorders (e.g. post-inflammatory hyperpigmentation, melasma) represent some of the most ubiquitous cutaneous concerns globally. In the U.S. alone, there are about 1.5 million visits for dyschromia annually. Few disease phenotypes are as visually compelling, or as challenging to treat, as chronic hyperpigmentation. Recent insights into melanocyte biology coupled with both rapid advances in molecular and biologic therapeutics and breakthroughs in device technology have now yielded unprecedented opportunities to “personalize” a corrective regimen. Clinical cases will be used to illustrate the mechanistic underpinnings of common pigmentary conditions along with the latest medical and surgical strategies for treatment.
- Kourosh, Arianne Shadi, MD, MPH: no financial relationships exist with commercial interests.
- Pandya, Amit G., MD: Aclaris Therapeutics Inc. – C(H); Clarify Medical Inc. – B(ST); Incyte Corporation – I(Grants/Research Funding); Pfizer Inc. – C(H);
- Saluja, Sandeep, MD: no financial relationships exist with commercial interests.
- Tsao, Sandy Sharon, MD: no financial relationships exist with commercial interests.